## CAH: Cardinal Health, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -5.5% below STRENGTH zone (4.0-10.0%); PEG 1.89 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($190.56)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. Bank of Nova Scotia Sells 163,493 Shares of Cardinal Health, Inc. $CAH**
- Source: MarketBeat | 20251209T085459 | Bullish | Relevance: 99%
- Bank of Nova Scotia significantly reduced its stake in Cardinal Health, Inc. (NYSE:CAH) by 49.7% in the second quarter, selling 163,493 shares and retaining 165,758 shares valued at approximately $27.85 million. Despite this reduction, other institutional investors increased their holdings, and overall institutional ownership stands at 87.17%. Analysts maintain a largely positive outlook with an average price target of $209, following a strong earnings beat and a declared quarterly dividend of $0.5107.

**2. Natixis Cuts Stock Position in Cardinal Health, Inc. $CAH**
- Source: MarketBeat | 20251209T130811 | Somewhat-Bullish | Relevance: 99%
-  Natixis reduced its stake in Cardinal Health, Inc. (NYSE:CAH) by 45.8% in the second quarter, selling 72,854 shares but still owning 86,051 shares valued at $14.46 million. Despite this, Cardinal Health reported strong Q2 earnings, beating analyst estimates with $2.55 EPS and setting positive FY2026 guidance, leading to a consensus "Moderate Buy" rating from analysts. Other institutional investors, however, increased their positions in the company, highlighting mixed sentiment among institutional holders.

**3. Barclays Initiates Coverage on Cardinal Health (CAH) with Overweight Rating**
- Source: Insider Monkey | 20251211T074007 | Bullish | Relevance: 99%
- Barclays analyst Glen Santangelo initiated coverage on Cardinal Health, Inc. (NYSE:CAH) with an Overweight rating and a $243 price target, noting the company's strong performance and strategic shift towards higher-margin healthcare areas. Cardinal Health has seen its stock climb nearly 68% in 2025 and reported a 22% increase in total revenue for fiscal Q1 2026. The company recently expanded its MSO platform with the acquisition of Solaris Health, enhancing its presence in the urology market.

**4. Investors in Cardinal Health (NYSE:CAH) have seen massive returns of 315% over the past five years**
- Source: Yahoo Finance | 20251211T080000 | Bullish | Relevance: 98%
- Cardinal Health shareholders have experienced impressive returns, with a 265% increase in stock price over five years and a total shareholder return (TSR) of 315% when accounting for dividends. The company transitioned from a loss to profitability during this period, indicating strong underlying business performance. Recent performance shows a 71% TSR over the last twelve months, surpassing the annualized return of the previous half-decade.

**5. Axa S.A. Sells 84,695 Shares of Cardinal Health, Inc. $CAH**
- Source: MarketBeat | 20251209T083059 | Bullish | Relevance: 98%
-  Axa S.A. has reduced its stake in Cardinal Health, Inc. (NYSE:CAH) by 15.2% during the 2nd quarter, selling 84,695 shares and now holding 472,833 shares valued at approximately $79.44 million. Despite this, Cardinal Health reported strong quarterly earnings, beating expectations with an EPS of $2.55 and revenue of $64.01 billion, and set a positive FY2026 guidance. Institutional ownership remains high at 87.17%, with several analysts raising price targets and a consensus "Moderate Buy" rating.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $243 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 11 ($0.00M) |
| Sells | 5 ($0.41M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Blackrock Inc.: 13.2% (+3.0%)
- Vanguard Group Inc: 13.0% (+0.8%)
- State Street Corpora: 5.2% (-3.0%)
- Geode Capital Manage: 2.7% (+1.5%)
- Wellington Managemen: 2.4% (+153.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.89 elevated, pricing in significant growth expectations. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $47.1B |
| Beta | 0.64 |
| 52W Range | $114.60 - $214.93 |
| Short Interest | 3.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.89 |
| Forward P/E | 17.9 |
| Current P/E | 20.2 |
| YoY Growth | 12.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 stable at -5.5% (minimal 5-day change). Below STRENGTH zone by 9.5pp (needs >4.0% for momentum thesis). AM_20 at -3.4% indicates price below own 20MA trend. Underperforming sector by 3.2pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.26x) but short-term weakness (below SMA20). MACD histogram bearish (-2.81), momentum weakening. RSI neutral at 51.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -5.47% (CS: 9) | Weak |
| RSI_14 | 50.6 | Neutral |
| MACD Histogram | -2.81 | Bearish |
| vs SMA20 | 0.966x | Below |
| vs SMA50 | 1.073x | Above |
| vs SMA200 | 1.260x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $198.32
- **Stop Loss:** $190.56 (3.9% risk)
- **Target:** $206.08 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 177
- **Position Value:** $35,102.64
- **Portfolio %:** 35.10%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-01-29 (Est: $2.30)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.17 | $2.55 | +17.3% |
| 2025Q2 | $2.03 | $2.08 | +2.4% |
| 2025Q1 | $2.15 | $2.35 | +9.4% |
| 2024Q4 | $1.76 | $1.93 | +9.4% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*